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Background: Radix Astragali is famous for its beneficial effect on inflammation associated diseases. This study was
to assess the efficacy of astragalosides (AST) extracted from Radix Astragali, on the progression of experimental
autoimmune encephalomyelitis (EAE), and explore its possible underlying molecular mechanisms.
Methods: EAE was induced by subcutaneous immunization of MOG35–55. Infiltration of inflammatory cells was
examined by HE staining. ROS level was detected by measuring infiltrated hydroethidine. Leakage of blood brain
barrier (BBB) was assessed using Evan’s blue dye extravasation method. Levels of inflammatory cytokines were
measured using ELISA kits. Activities of total-SOD, GSH-Px, and iNOS and MDA concentration were measured using
biochemical analytic kits. Gene expression was detected using real-time PCR method. Protein expression was
assayed using western blotting approach.
Results: AST administration attenuated the progression of EAE in mice remarkably. Further studies manifested that AST
treatment inhibited infiltration of inflammatory cells, lessened ROS production and decreased BBB leakage. In peripheral
immune-systems, AST up-regulated mRNA expression of transcriptional factors T-bet and Foxp3 but decreased that
of RORγt to modulate T cell differentiation. In CNS, AST stopped BBB leakage, reduced ROS production by up-regulation
of T-SOD, and reduced neuroinflammation by inhibition of iNOS and other inflammatory cytokines. Moreover, AST
inhibited production of p53 and phosphorylation of tau by modulation of the Bcl-2/Bax ratio.
Conclusions: AST orchestrated multiple pathways, including immuno-regulation, anti-oxidative stress, anti-
neuroinflammation and anti-neuroapoptosis involved in the MS pathogenesis, to prevent the deterioration of EAE,
which paves the way for the application of it in clinical prevention/therapy of MS.
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Multiple sclerosis (MS), a chronic inflammatory demyelin-
ating disease of central nervous system (CNS), generally
manifests in an initial relapsing-remitting clinical course
that culminates in permanent neurological damage. It is
found mostly in young adults in the western world [1,2].
The main pathological features of the disease include focal
CNS inflammation with axonal demyelination and neur-
onal death [3]. The common clinical strategy for therapy
of acute relapses in MS is either by high dose, short-term
pulse therapy with glucocorticoid [4] or by immunomodu-
latory treatments such as interferon beta [5], glatiramer
acetate [6], and mitoxantrone [7]. In addition, immuno-
suppression therapy with drugs such as azathioprine [8],
cyclophosphamide [9] and intravenous immune globulin
(IVIG) [10] as well as plasmapheresis [11] have also been
suggested. Other novel treatments still requiring further
clinical trials are estriol [12], statins [13] and natalizumab
[14]. Although these drugs can slow down MS progression
and ameliorate intensity of relapsed disease, however,
long-term therapy with these drugs often gives rise to sig-
nificant adverse effects including depression, infection,
cardiotoxicity, nausea and anemia [15]. Therefore, new
therapy with high efficacy but low side-effect is urgently
needed for MS treatment.
Experimental autoimmune encephalomyelitis (EAE) is
the most widely used animal model to study the patho-
genesis and therapeutic interventions of MS. The model
can be actively induced by immunizing the animals with
different antigenic materials from CNS homogenate,
myelin proteins, fusion proteins to small encephalito-
genic peptides [16,17]. Alternatively, autoreactive T cells
from immunized animals can be adoptively transferred
into naïve animals to induce the disease. Generally, the
typical clinical course of EAE exhibits as weight loss, as-
cending progressive paralysis, and then spontaneous re-
covery [18]. More importantly, the model mimics the
major neuropathological features of MS in histopath-
ology such as inflammation, demyelination, axonal loss
and gliosis.
Radix Astragali is the root of Astragalus membranaceus
Bunge which has been used widely as a key remedy in
traditional Chinese medicine for its anti-inflammatory,
anti-oxidative, immune-regulatory, and neuro-protective
activities [19,20]. Astragalosides (AST) are the principle
bioactive components extracted from roots of Radix As-
tragali. Recent pharmacological studies have shown that
AST benefits the axonal regeneration or growth of both
peripheral and central nervous systems. When used at low
concentration, AST is salutary in aiding the growth of
axons of sciatic nerve [21]. In aged rodents, AST treat-
ment facilitates the recovery of learning and memory im-
pairments [22,23]. Moreover, a recent report suggests that
intravenous infusion of AST in healthy Chinese volunteersis safe and well tolerated [24]. Therefore, AST seems to be
an efficient and safe prodrug for the therapy of neuro-
logical diseases associated with inflammation.
Astragaloside IV (ASI), one of the single compounds
within AST, has been found to attenuate the progression
of EAE [25]. However, since ASI within AST was less
than 5% according to our study, therefore, whether AST
has similar effect has not been known yet. In current
study, the effect of AST on C57BL/6 mice induced with
EAE by MOG35–55 was assessed and compared with that
of ASI. Our results demonstrated that AST alleviated the
severity of EAE, the efficacy of which was better than
that of ASI at the same dose. Thereafter, the underlying
mechanisms were discussed from multi-levels involved
in the MS pathophsiology, including anti-oxidative stress,
anti-inflammation, anti-apoptosis, and immunoregulation.
These novel findings provide a new insight into the poten-




Decoction pieces of the roots of Astragalus membranaceus
(Fisch.) Bge were provided by Shanghai Yanghetang Elec-
tuary Factory (Shanghai, China) and authenticated by Dr.
Hong Xu, Institute of Chinese Materia Medica, Shanghai
University of Traditional Chinese Medicine. AST was pre-
pared and purified according to the method mentioned
previously [26]. In brief, the 70% ethanol fraction of A.
membranaceus was sequentially extracted with n-BuOH,
purified with macroporous resin, followed by precipitation
with diethyl ether:acetone (1:1). The resultant AST was
subjected to HPLC analysis to determine the major com-
ponents as described previously [26]. The percentages of
astragaloside I, II and IV in the prepared AST were found
to be 76.1, 9.3 and 3.7, respectively.
EAE induction and AST treatment
The animal experiments were carried out according to the
protocols approved by University Animal Care and Use
Committee of Shanghai University of Traditional Chinese
Medicine. EAE induction was performed in 6-weeks-old
female C57BL/6 mice as described previously [25]. Each
mouse received 100 μl of complete Freund’s adjuvant
emulsified with 300 μg MOG35–55 and 400 μg of heat-
inactivated Mycobacterium tuberculosis H37RA via sub-
cutaneous injection. Pertussis toxin (200 ng/mouse) was
administered intraperitoneally (i.p.) immediately and again
two days later. Clinical behavior of mice was scored daily
in accordance with the criteria described by Peiris et al.
[27]. And the day of immunization was considered as
EAE day 0.
Daily AST treatments (10, 25, and 50 mg/kg) or ASI
(10 mg/kg) were administered i.p. from day 0 to day 14.
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control drug was given i.p. at 20 mg/kg dosage for three
consecutive days from day 8 to day 10 post-immunization.
Histopathology
Mice were anesthetized with 20% urethane and then per-
fused intracardially with PBS followed by 4% paraformal-
dehyde. Cross sections of spinal cords at 20 μm thickness
were obtained on a Leica 1950 cryostat. Hematoxylin and
eosin (HE) staining was conducted to evaluate the extent
of infiltration of inflammatory cells.
Western Blot
Protein samples were obtained by homogenizing brain
cortices of mice in CelLytic™ MT mammalian tissue lysis
reagent (Sigma, C3228) mixed with protease inhibitor
cocktail (Sigma, P3840) and phosphatase inhibitor cocktail
2 (Sigma, P5726). The homogenate was centrifuged at
12,000 rpm for 10 min at 4°C. The concentration of the
protein was quantified by BCA assay. After being electro-
phoresed on 12% SDS-PAGE gel, the proteins were trans-
ferred onto FluoroTrans® W PVDF membranes (Pall,
20685) via electrophoretic transfer system (Bio-Rad). Then
the membranes were blocked with 5% skim milk in PBST
for 1 hr followed by incubation with respective primary
antibodies at 4°C overnight. After thoroughly washed with
PBST, the membranes were further incubated with re-
spective horseradish peroxidase conjugated secondary
antibodies. Thereafter, the protein bands were visualized
with ECL-prime kit.
Cytokine quantification
The brain cortices of mice were homogenized in PBS
(1:10 w/v) on ice. After being centrifuged at 4000 rpm
for 10 min at 4°C, the supernatants were subjected to
further ELISA analysis. The concentrations of IFNγ,
TNFα, IL6, IL4, and IL17A in brain homogenates were
determined using respective ELISA kits referred to the
manuals of manufacturer (eBiosciences, San Diego, CA).
The cytokine concentrations of respective samples were
quantified by standard curves prepared by recombinant
cytokines of known concentrations.
Evan’s blue dye extravasation
To determine the permeability of BBB, the Evan’s blue
(EB) dye extravasation method was used as described pre-
viously [25]. Briefly, the mice were i.p. injected with 400 μl
of 0.8% EB in PBS. Two hours later, the mice were anes-
thetized with 20% urethane and the brains were dissected
and weighed. Hemispheres of brains were homogenized in
1 ml of 50% TCA. After centrifugation at 12,000 rpm for
10 min, the supernatants were collected and subjected to
fluorescent intensity detection on a microplate fluores-
cence reader (excitation :620 nm, emission: 680 nm).Reactive oxygen species (ROS) measurements
To assess the ROS level in brain, hydroethidine, the
superoxide-sensitive fluorescent probe, was utilized. It is
easily oxidized by superoxide into dihydroethidine
(DHE), fluorescence of which can be detected by a fluor-
escence reader. Mice were injected i.p. with 200 μl of
1 mg/ml hydroethidine for 15 min. Thereafter, they were
anesthetized with excessive 20% urethane and sacrificed.
The brain cortices were dissected and homogenized in
CelLyticTM MT mammalian tissue lysis reagent contain-
ing protease inhibitor cocktail and phosphatase inhibitor
cocktail 2 (1:5, w/v). After centrifugation at 12,000 rpm
for 10 min, the supernatants were collected and sub-
jected to fluorescent detection using a Varioskan flash
spectral scanning multimode reader (Thermo, excitation
:540 nm; emission: 595 nm).
Biochemical analysis
Samples of brain cortices were prepared as mentioned
above in cytokine quantification section. Activities of
glutathione peroxidase (GSH-Px), total superoxide dis-
mutase (T-SOD), and inducible nitric oxide synthase
(iNOS) and the concentration of malondialdehyde
(MDA) in the samples were analyzed with respective kits
according to the manuals of manufacturer (Jiancheng
Bioengineering Institute, Nanjing, China).
Quantitative PCR
Hippocampal total RNA of mice was extracted using RNa-
zol according to the manufacturer’s manuals (Takara, Da-
lian, China). After removal of the trace amounts of DNA
contamination with DNase I, total RNA was reverse tran-
scripted into cDNA with kit from Life Technologies (Grand
Island, NY, USA). Quantitative PCR was carried out using
Taqman SYBR kit (Life Technologies). The concentrations
of target genes in the samples were determined by standard
curves generated with template plasmids including frag-
ments of the related target genes. At last, they were normal-
ized to that of glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) in the same sample. The sequences for all the
primers used were described as previously [25].
Statistical analysis
All data in the graphs were presented as mean ± stand-
ard error of mean. Statistical comparisons were carried
out by one-way analysis of variance (ANOVA) followed
by Tukey's post-hoc test using GraphPad Prism 5 soft-
ware (La Jolla, CA, USA ). Differences were considered
as statistically significant when p < 0.05.
Results
AST attenuated severity of EAE mice
Generally, the onset of EAE was started from day 8 after
MOG35–55 immunization in our experiments. To evaluate
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the average behavioral scores of mice from day 8 to day
21 post-immunization among groups were compared.
As shown in Figure 1A, MPD, the positive control
drug, remarkably alleviated the severity of the disease
(p < 0.001). AST, when used at doses of 10, 25 and
50 mg/kg, improved the clinical behavioral symptoms
of EAE mice significantly (p < 0.001). Meanwhile, AST
when used at 25 and 50 mg/kg dosages did not show
any difference with MPD regarding the alleviation of
EAE severity. However, EAE mice treated with lowFigure 1 Effects of AST on EAE progression and body weight in mice
administered at three different dosages (H: 50 mg/kg/day, M: 25 mg/kg/da
and lasted for 14 days as well as ASI (10 mg/kg/day). Methylprednisolone (
from the day 8 to day 10 post-immunization. B) Change of body weight am
error of mean (n = 14). **p < 0.01; ***p < 0.001 vs EAE group.dose of AST (10 mg/kg) exhibited marked difference
with those treated with MPD (p < 0.01).
To examine if the alleviation of EAE by AST was due
to ASI it contained, an additional ASI-treated group
mice was compared with other AST treated ones. As il-
lustrated in Figure 1A, ASI used at 10 mg/kg also atten-
uated the deterioration of EAE significantly (p < 0.001),
however, its effect seemed to be weaker than that of the
middle- and high-dose of AST.
In addition, AST treatment prevented the continu-
ously body weight loss of EAE mice. As illustrated in. A) Comparison of mean clinical scores after EAE induction. AST was
y, L: 10 mg/kg/day) i.p. from the day before MOG35–55 immunization
MPD) served as positive control drug was given at 50 mg/kg/day i.p.
ong different group mice. All data are presented as mean ± standard
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showed prominently body weight loss in two weeks
post-immunization and thereafter (p < 0.001). However,
AST administration (50 mg/kg) reversed the trend. As
shown in Figure 1B, body weight of AST treated EAE
mice was gradually increased after MOG immunization.
AST prevented inflammatory cell infiltration in EAE mice
To evaluate the effects of AST (50 mg/kg) on inflamma-
tory cell infiltration in EAE mice, sections of spinal
cords of mice were subjected to HE staining. As shown
in Figure 2, results from HE staining demonstrated the
remarkable infiltration of inflammatory cells in the
meanings and parenchymal tissues of spinal cords in
EAE mice. By contrast, AST treatment prevented the in-
filtration of those inflammatory cells.
AST decreased ROS stress in EAE mice
Leakage of BBB and increased oxidative stress are typical
phenomena occurred in the pathogenesis of EAE [28]. In
our study, the permeability of BBB was assessed by infil-
trated Evan’s blue dye. In concordance with previous re-
ports, EAE caused the leakage of BBB even three weeks
post-immunization (p < 0.05, Figure 3A). Meanwhile, EAE
induced significantly elevated ROS level in CNS of mice. As
shown in Figure 3B, fluorescent intensity of infiltrated DHE
in EAE mice was increased prominently (p < 0.01), which
was accompanied with markedly down-regulated GSH-Px
(p < 0.05, Figure 3C) and T-SOD (p < 0.05, Figure 3D)
but up-regulated iNOS (p < 0.01, Figure 3E) activity. As a
result, MDA, the breakdown product of oxidation ofFigure 2 Effect of AST on inflammatory infiltration of EAE mice. Pictur
50 mg/kg/day. Bars in pictures represent 100 μm.polyunsaturated fatty acids and reliable oxidant marker of
oxidative stress-mediated lipid peroxidation [29] generated
in brain cortices of EAE mice was increased significantly
(p < 0.05, Figure 3F). AST treatment ameliorated the
increased BBB leakage of EAE mice (p < 0.05). Although
AST did not elevate the activity of GSH-Px, it increased
T-SOD activity remarkably (p < 0.01, Figure 3C-D). More-
over, up-regulated iNOS activity was inhibited by AST
administration (p < 0.05, Figure 3E). Accordingly, MDA
produced in AST treated mice tended to be reduced in
spite of no difference in statistics with that in EAE mice re-
ceived no treatment (Figure 3F).
AST affected mRNA expression of hippocampal GFAP,
CD11b and iNOS
GFAP and CD11b are astroglial and microglial markers in
CNS, respectively. EAE caused significantly enhanced
mRNA expression of both GFAP (p < 0.01, Figure 4A) and
CD11b (p < 0.001, Figure 4B) in hippocampus. Meanwhile,
mRNA expression of iNOS was also up-regulated (p < 0.01,
Figure 4C). When AST was administered, the GFAP,
CD11b, and iNOS mRNA expression of EAE mice were all
down-regulated significantly (p < 0.05, p < 0.01, and p < 0.01,
respectively, Figure 4A-C).
AST affected mRNA expression of splenic RORγt, T-bet,
and Foxp3
RORγt, T-bet and Foxp3 are transcription factors associ-
ated with the differentiation of CD4+ T cells into Th1,
Th17 and Treg effector cells. In our study, the signifi-
cant increase of RORγt mRNA expression in spleens ofes denoted HE staining of spinal cords. The dose of AST used was
Figure 3 Effect of AST on permeability of BBB and ROS level. A) AST decreased permeability of BBB in EAE mice examined by Evan’s blue
dye infiltration. B) AST reduced ROS release in cortices of EAE mice measured by DHE fluorescent intensity. C) AST did not increase GSH-Px
activity in cortices of EAE mice. D) AST up-regulated T-SOD activity in cortices of EAE mice. E, F) AST inhibited elevated iNOS and MDA in cortices
of EAE mice. The dose of AST used was 50 mg/kg/day. All data are presented as mean ± standard error of mean. n = 5 in each group. *p < 0.05;
**p < 0.01; ***p < 0.001 vs EAE group.
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administration (50 mg/kg). Although splenic mRNA ex-
pression of T-bet did not change in EAE mice, it
was prominently elevated by AST treatment (p < 0.05,
Figure 5B). Meanwhile, splenic Foxp3 mRNA expression
was down-regulated in EAE mice, which was compen-
sated remarkably by AST treatment (p < 0.01, Figure 5C).AST regulated cytokine profile of EAE mice
To assess the effect of AST on cytokine profile of EAE
mice, brain cortices of mice three weeks post-immunization
were homogenized and the supernatants after centrifuga-
tion were subjected to respective cytokine analysis using
different ELISA kits. As shown in Figure 6, concentrations
of most cytokines examined including TNFα, IL6, IL4 and
IL17A in EAE mice did not differ from that in control mice
except IFNγ (p < 0.05). AST treatment did not affect IL4
and IL17A concentrations in brain cortices of EAE mice.However, it decreased IFNγ (p < 0.01), TNFα (p < 0.01) and
IL6 (p < 0.05) levels.AST modulated expression of apoptotic proteins in CNS
Neuronal injury caused by infiltrated inflammatory T cells
is a common feature of EAE. To evaluate the effect of
AST treatment on neuronal damage, expression of pro-
teins associated with neuronal apoptosis in cortices of
mice were analyzed. Consistent with the mRNA expres-
sion pattern, GFAP protein expression in EAE mice was
elevated markedly (p < 0.001, Figure 7). The pro-apoptotic
protein, p53, was also up-regulated (p < 0.05). Accordingly,
the phosphorylated tau protein that indicates the extent of
neuronal injury was increased prominently (p < 0.01). Ex-
pression of Bax, one of the members of Bcl-2 family, was
also enhanced. On the contrary, Bcl-2, the anti-apoptotic
protein, was inhibited in EAE mice. AST treatment
(50 mg/kg) prevented further neuroinflammation and
Figure 4 Effect of AST on hippocampal mRNA expression of
GFAP, CD11b and iNOS in EAE mice. A) AST inhibited GFAP
mRNA expression. B) AST reduced CD11b mRNA expression. C) AST
prevented iNOS mRNA expression. All data are presented as mean ±
standard error of mean. The dose of AST used was 50 mg/kg/day. n
= 5 in each group. *p < 0.05; **p < 0.01 vs EAE group.
Figure 5 Effect of AST on splenic mRNA expression of RORγt, T-
bet, and Foxp3 of EAE mice. A) AST inhibited RORγt mRNA
expression. B) AST increased T-bet mRNA expression. C) AST ele-
vated Foxp3 mRNA expression. All data are presented as mean ±
standard error of the mean. The dose of AST used was 50 mg/kg/
day. n = 5 in each group. *p < 0.05; **p < 0.01; ***p < 0.001 vs
EAE group.
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Figure 6 Effect of AST on cytokine profile in cortices of EAE mice. All data are presented as mean ± standard error of mean. The dose of AST
used was 50 mg/kg/day. n = 5 in each group. *p <0.05; **p < 0.01 vs EAE group.
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without any treatment, protein expression of GFAP and
p53 in AST treated EAE mice were inhibited remarkably
(p < 0.05). Although Bax expression was not inhibited by
AST treatment, the ratio of Bcl-2 to Bax was significantly
increased (p < 0.01). Therefore, the phosphorylation of tau
in EAE mice was prevented markedly (p < 0.001).
Discussion
In present study, AST treatment attenuated the progres-
sion of EAE mice significantly. Further studies demon-
strated that multiple pathways mediated the preventive
effect of AST. Increased inflammatory cell infiltration,
BBB leakage, and ROS level in CNS were the significant
features of EAE mice. AST administration counteracted
the harmful effect by modulating the differentiation of T
cells, increase of anti-oxidant enzymes, and inhibition of
neuroinflammation. In addition, in CNS it mitigated the
neuronal apoptosis during EAE by modulating the ratio
of Bcl-2 to Bax, therefore, reduced the phosphorylation
of tau and thus neuronal damages in CNS.
AST was the total astragalosides extracted from A.
membranaceus that mainly composed of astragaloside I,
II and IV according to our analysis. And astragaloside I
was the major component within AST (>76%). How-
ever, since AST also contained 3.7% astragaloside IV
(ASI), the compound that had been reported by our
group to alleviate the progression of EAE [25], the ef-
fect of AST on EAE might be due to ASI. To examine
the possibility, we added one group of EAE mice treated
with ASI (10 mg/kg). According to our result, not sur-
prisingly, ASI prevented the aggravation of EAE as we
reported previously. However, the effect of ASI seemed
to be weaker than AST (25 mg/kg and 50 mg/kg), which
contained less than 2 mg/kg of ASI. These findingsindicated that other components besides ASI in AST
might also contribute to the alleviative effect, or that
many ingredients of AST may have a synergistic allevia-
tive effect, which should be investigated in further
studies.
T helper cell subsets, Th1, Th17 and Tregs (regulatory
T-cells), play essential regulatory roles in MS or EAE
pathogenesis. EAE was easily induced in mice adoptively
transferred with MOG-specific Th1 cells [30]. Recently,
Th17 cells are thought to have a pivotal role in the
pathogenesis of EAE. In vitro differentiated Th17 cells,
when adoptively transferred to mice, will form specific
immune synapse-like contacts with neurons and induce
the death of latter [31]. By contrast, the induction or
transplant of Tregs leads to reduction of disease severity
in EAE [32]. Transcriptional factors, T-bet, RORγt and
Foxp3, contribute to the differentiation of CD4 naïve T
cells into respective subsets. In the presence of IL12 and
expression of T-bet, Th1 cells can be generated from
naïve T cells; when transforming growth factor (TGF)-β
plus IL 6 are present with the expression of RORγt,
Th17 cells will be generated [33]. Foxp3, as a master
regulator, is important for the development and function
of Tregs [34]. In our experiments, all of the three tran-
scriptional factors were modulated by AST administra-
tion at mRNA levels (Figure 5), which indicated the role
of AST in control of the differentiation of naïve T cells.
Therefore, there were less inflammatory T cells infil-
trated into CNS of EAE mice after treatment with AST
(Figure 2).
Opening or breakdown of BBB has been known to be
involved in the pathogenesis of MS or EAE [35,36].
Meanwhile, ROS leading to oxidative stress that is pro-
duced primarily by infiltrated macrophages have been
suggested as mediators of demyelination and axonal
Figure 7 Effect of AST on expression of apoptotic proteins in cortices of EAE mice. A) Typical bands of GFAP, Bcl-2, Bax, p53, p-tau and
tau in cortices of EAE mice treated with AST detected by western blotting. B) Gray intensity analysis of GFAP, Bcl-2, p53 and p-tau. All data are
presented as mean ± standard error of mean. The dose of AST used was 50 mg/kg/day. n = 5 for each group. *p < 0.05; **p < 0.01; ***p < 0.001 vs
EAE group.
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can cause enhanced permeability of the BBB [38]. Con-
sistent with the reports, our study showed that EAE pro-
gression caused marked leakage of BBB and elevation
of ROS in CNS (Figure 3). As a result, both of MDA
and phosphorylated tau, the indicators to evaluate the
extent of neuronal damage, were accumulated signifi-
cantly (Figures 3 and 7). AST administration prevented
the leakage of BBB and reduced ROS level in CNS. Both
of GSH-Px and T-SOD function as part of anti-oxidant
defense system. Our studies disclosed that AST mainlyincreased the activity of T-SOD but not GSH-Px, there-
fore, enhanced the ROS scavenging capacity of CNS.
Gliosis, i.e. astrocytosis and microgliosis, within and
around the inflammatory demyelinating lesions is one
of the prominent features of both MS and EAE [39,40].
Reactive astrocytes on the one hand trigger innate pro-
inflammatory response after CNS injury and on the
other hand form scar-like perivascular barriers to re-
strict the influx of leukocytes into CNS parenchyma
[41]. As the innate immune cells in CNS, microglia are
necessary for normal brain function to help host defense
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debris, accelerating tissue repair and facilitating tissue
homeostasis [42]. However, uncontrolled and sustained
activation of microglia will generate excessive detrimental
substances such as nitric oxide, free radicals and proin-
flammatory cytokines that finally result in neuronal de-
struction [43]. In our experiments, significantly increased
mRNA levels of both GFAP and CD11b were found in
CNS of EAE mice accompanied with elevated iNOS activ-
ity, which indicated the occurrence of neuroinflammation.
After AST treatment, the activation of astrocytes and
microglia cells was inhibited as the mRNA levels of both
GFAP and CD11b were reduced remarkably (Figure 4).
p53 plays a suppressive role in the inflammatory re-
sponse by regulation the cytokine profile as well as the
destiny of infiltrated cells [43]. Abnormalities in p53 at
the lesion site may influence the severity or chronicity of
MS [44]. Deficiency of p53 increases the severity of EAE
possibly by elongating the survival of inflammatory cells
in the CNS, therefore, enhancing the production of pro-
inflammatory cytokines such as IL-6, TNF-α and IFN-γ.
In current study, p53 level was elevated markedly in CNS
of EAE mice but accompanied with increased IFN-γ,
which might reflect a self-defense mechanism in anti-
inflammation. AST administration prohibited further neu-
roinflammation as the production of IFN-γ, TNF-α and IL
6 was inhibited significantly. Meanwhile, the level of p53
was resumed to normal condition.
Both Bcl-2 and Bax belong to Bcl-2 family but play dif-
ferent role in control of apoptotic cascade of cells. The
balance of them determines the fate of cells toward sur-
vival or death, therefore, the ratio of Bcl-2 to Bax is a
better determinant to evaluate the apoptotic tendency of
cells [44,45]. In our study, Bax was found to be elevated
significantly in CNS of EAE mice (Figure 7). AST treat-
ment did not mitigate the level of Bax but recovered or
prevented the degradation of Bcl-2 relatively, therefore,
increased the ratio of Bcl-2 to Bax. As a result, the phos-
phorylated tau protein in CNS was decreased remark-
ably. Pathological hyperphosphorylation and aggregation
of microtubule-associated protein tau is a common char-
acter of many neurodegenerative diseases with axonal
degeneration including MS [45].
Conclusion
In summary, AST administration alleviated the progression
of EAE by interfering multiple aspects involved in the MS
pathogenesis, including immuno-regulation, anti-oxidative
stress, anti-neuroinflammation and anti-neuroapoptosis.
This study paves the elementary way for the potential ap-
plication of AST in clinical intervention of MS.
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